Literature DB >> 34541899

Rho GTPase signaling in cancer progression and dissemination.

Eva Crosas-Molist1, Remi Samain1, Leonie Kohlhammer1, Jose L Orgaz1,2, Samantha L George1, Oscar Maiques1, Jaume Barcelo1, Victoria Sanz-Moreno1.   

Abstract

Rho GTPases are a family of small G proteins that regulate a wide array of cellular processes related to their key roles controlling the cytoskeleton. Cancer is a multistep disease caused by the accumulation of genetic mutations and epigenetic alterations, from the initial stages of cancer development when cells in normal tissues undergo transformation, to the acquisition of invasive and metastatic traits, responsible for a large number of cancer related deaths. In this review, we discuss the role of Rho GTPase signaling in cancer in every step of disease progression. Rho GTPases contribute to tumor initiation and progression, by regulating proliferation and apoptosis, but also metabolism, senescence, and cancer cell stemness. Rho GTPases play a major role in cell migration and in the metastatic process. They are also involved in interactions with the tumor microenvironment and regulate inflammation, contributing to cancer progression. After years of intensive research, we highlight the importance of relevant models in the Rho GTPase field, and we reflect on the therapeutic opportunities arising for cancer patients.

Entities:  

Keywords:  Rho GTPases; cancer; clinical opportunities; signaling

Mesh:

Substances:

Year:  2021        PMID: 34541899     DOI: 10.1152/physrev.00045.2020

Source DB:  PubMed          Journal:  Physiol Rev        ISSN: 0031-9333            Impact factor:   37.312


  9 in total

1.  Is Cryptosporidium a hijacker able to drive cancer cell proliferation?

Authors:  Gabriela Certad
Journal:  Food Waterborne Parasitol       Date:  2022-04-14

Review 2.  Rac1 as a Target to Treat Dysfunctions and Cancer of the Bladder.

Authors:  Vincent Sauzeau; Julien Beignet; Christian Bailly
Journal:  Biomedicines       Date:  2022-06-08

3.  Differential Impact of Membrane-Bound and Soluble Forms of the Prognostic Marker Syndecan-1 on the Invasiveness, Migration, Apoptosis, and Proliferation of Cervical Cancer Cells.

Authors:  Katharina Hilgers; Sherif Abdelaziz Ibrahim; Ludwig Kiesel; Burkhard Greve; Nancy A Espinoza-Sánchez; Martin Götte
Journal:  Front Oncol       Date:  2022-01-27       Impact factor: 6.244

4.  Long noncoding RNA LINC00857 promotes pancreatic cancer proliferation and metastasis by regulating the miR-130b/RHOA axis.

Authors:  Peng Chen; Zhirui Zeng; Jie Wang; Wenpeng Cao; Chunzhuo Song; Shan Lei; Yichuan Li; Zhangxia Ren
Journal:  Cell Death Discov       Date:  2022-04-13

5.  Genomic Analysis of Abnormal DNAM Methylation in Parathyroid Tumors.

Authors:  Qing Li; Yonghao Li; Ximei Sun; Xinlei Zhang; Mei Zhang
Journal:  Int J Endocrinol       Date:  2022-07-16       Impact factor: 2.803

6.  Proteotranscriptomics of ocular adnexal B-cell lymphoma reveals an oncogenic role of alternative splicing and identifies a diagnostic marker.

Authors:  Jiahao Shi; Tianyu Zhu; Huimin Lin; Zhen Liu; Min Zhou; Ziyao Yu; Xiaowen Zhou; Xin Song; Yefei Wang; Renbing Jia; Xianqun Fan; Yixiong Zhou
Journal:  J Exp Clin Cancer Res       Date:  2022-07-30

7.  RHOA protein expression correlates with clinical features in gastric cancer: a systematic review and meta-analysis.

Authors:  Seungyoon Nam; Yeeun Lee; Jung Ho Kim
Journal:  BMC Cancer       Date:  2022-07-19       Impact factor: 4.638

8.  The relation of blood cell division control protein 42 level with disease risk, comorbidity, tumor features/markers, and prognosis in colorectal cancer patients.

Authors:  Shuquan Gao; Jun Xue; Xueliang Wu; Tingting Zhong; Yingchun Zhang; Shaodong Li
Journal:  J Clin Lab Anal       Date:  2022-06-23       Impact factor: 3.124

Review 9.  Biochemical Pathways of Cellular Mechanosensing/Mechanotransduction and Their Role in Neurodegenerative Diseases Pathogenesis.

Authors:  Ilaria Tortorella; Chiara Argentati; Carla Emiliani; Francesco Morena; Sabata Martino
Journal:  Cells       Date:  2022-10-01       Impact factor: 7.666

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.